New research indicates that patients who discontinue popular weight-loss injections like Wegovy and Mounjaro can put back on shed pounds far faster than those who halt traditional lifestyle plans.
Findings released in a major health publication points out that while overweight people frequently drop substantial amounts of their total mass while using the jabs, the weight is regained at an estimated rate of nearly a kilo each month upon discontinuation.
"People purchasing these drugs should be cognizant of the risk of quick weight regain when the medication ends," cautioned expert Dr. Susan Jebb.
That rate of recovery implies a return to pre-treatment mass within about one and a half years.
Analyzing Therapies
The analysis, which reviewed 37 of studies involving thousands of participants, contrasted the outcomes of GLP-1 agonists with other pills.
Scientists emphasize that individuals who shed pounds through dieting generally have a less rapid creep back—approximately 0.1 kg a month—once they finish.
The Reason for the Quick Rebound
Experts suggest the mechanism of the injections accounts for the accelerated regain.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Artificially providing the hormone levels several times higher than the body's typical production might result in the body to generate a reduced amount of its endogenous hormone, and may also reduce responsiveness to its actions," said Dr. Adam Collins, a nutrition researcher.
"Stopping of this GLP-1 'fix' results in hunger is uncontrolled, making binge eating much more probable."
An Ongoing Disease?
The NHS suggest the jabs for people with obesity-related health risks, alongside prescribed diet and exercise modifications.
Many experts contend that, given the high risk of relapse, the treatment is often life-long.
This opinion is echoed by pharmaceutical companies, who state that the results "underscore the chronic nature of obesity," akin to managing diseases like diabetes.
Patient Experiences
People who have discontinued the medication report a intense return of appetite.
"It felt as if a trigger flipping and you become extremely hungry," said a patient.
This challenge is worsened if individuals have not adopted sustainable lifestyle or habit modifications during treatment.
Widespread Interest
Survey data show that a significant number of adults in the UK have used these injections in the past year, with desire remaining high.
- Adoption is greater among females than men.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
In conclusion, clinicians emphasize that while GLP-1 drugs are powerful tools for weight loss, they are not a magic solution and long-term success relies on integrated lifestyle changes.
